Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has enrolled 8 patients to date in its Phase 2 RENEW trial evaluating LTI-03 for idiopathic pulmonary fibrosis, with two additional patients expected this week. Enrollment began in March 2026 and continues on a regular basis across an expanding global footprint. Clinical sites are currently active in the United States, Australia, and Poland, with the United Kingdom and Germany expected to open in the near term to support ongoing recruitment.
Key figures
- Drug Name
- LTI-03
- Phase Of Trial
- Phase 2
- Patients enrolled
- 8
- Target enrollment
- 120
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.